We studied the defect responsible for deficiency of the b subunit for factor XIII in the first known case of this condition. The patient is a compound heterozygote of two genetic defects: deletion of A-4161 at the acceptor splice junction of intron A, resulting in a loss of the obligatory AG splicing sequence; and, replacement of G-11499 by T in exon VIII, resulting in an amino acid substitution of Cys430 by Phe. To determine how the latter mutation impaired b subunit synthesis, recombinant b subunit bearing the mutation was expressed in BHK cells. The mutant as well as wild-type b subunit was synthesized by the cells. However, the apparent molecular weight of the mutant was slightly higher than those of the wild-type and plasma b subunits under nonreducing conditions, probably because of destruction of a disulfide bond. The mutant b subunit was secreted from the cells much less effectively than the wild type and remained susceptible to endoglycosidase H, indicating that it was not transported from the endoplasmic reticulum to the Golgi apparatus where the processing of oligosaccharides occurs. Immunofluorescence study suggested that the mutant protein was retained in the endoplasmic reticulum. These studies demonstrate that a Cys430-Phe mutation does not prevent the de novo synthesis of the b subunit, but alters the conformation of the mutant protein sufficiently to impair its intracellular transport, resulting in its deficiency in this patient. (J. Clin. Invest. 1995. 95:1002-1008
Introduction
Coagulation factor XIII is a plasma transglutaminase consisting of two catalytic a and two noncatalytic b subunits. The a subunit is also present as an a2 dimer in platelets/megakaryocytes, monocytes/macrophages, skin dendrocytes, placenta, and prostate, whereas the b subunit is synthesized in hepatocytes (for reviews see references [1] [2] [3] . Since the a subunit carries the active site of the enzyme, its deficiency leads directly to defective cross-linking reactions and, as a consequence, to bleeding, abnormal wound healing, and spontaneous abortion in females. Intracranial bleeding is the leading cause of death in factor XIII deficiency. Although many cases of factor XIII deficiency have been reported, most of them are deficiencies of the a subunit. Recently, the first patient with complete deficiency of the b subunit was found in Japan (4) . The patient also has a reduced plasma level of the a subunit and manifests a mild bleeding tendency. It is highly likely that the lack of the b subunit resulted in the loss of the a subunit because of its instability. Indeed, an accelerated half-life of therapeutic exogenous a subunit has been observed in this patient.
The amino acid sequence of factor XIII has been established by a combination of gene cloning and amino acid sequence analysis (5) (6) (7) (8) . The a subunit consists of 731 amino acids, while the b subunit is composed of 641 residues which form ten tandem repeats called Sushi domains or GP-I structures (9) . Determination of the genomic sequence for both a and b subunits has made it possible to characterize factor XIII deficiency at the genetic level (10) (11) (12) (13) (14) . Genomic DNAs obtained from the proband of complete b subunit deficiency (4) and her family members have been examined by Southem blotting analysis and in vitro amplification employing gene-specific primers (14) . DNA sequence analysis revealed that an adenosine was deleted in half of the amplified DNAs at the acceptor splice junction of intron A, resulting in a loss of the obligatory AG splicing sequence (see Fig. 3 in reference 14). Furthermore, a guanosine coding for Cys430(TGC) in exon VIII was replaced by a thymidine in half of the amplified DNAs, resulting in an amino acid change to Phe(TTC) and destruction of a disulfide bond in the seventh Sushi domain of the b subunit. Thus, the proband was a genotypic compound heterozygote of two defects. Her (16) . The mutation in the cDNA was confirmed by dideoxy sequencing and the cDNA was then inserted into ZMB3 (Fig. 1) . The constructed expression vectors for the wild type and mutant b subunits were designated ZMB3/XIIIb and ZMB3/ MXIIIb, respectively.
Cell culture and transfection. Baby hamster kidney (BHK) cells were grown in Dulbecco's modified Eagle medium (DME) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 50 isg/ ml penicillin, 50 ug/ml streptomycin, and 100 I g/ml neomycin (GIBCO BRL, Gaithersburg, MD). For transient expression, approximately 3 x 106 BHK cells were transfected with 10 ,ug of the expression plasmid, ZMB3/XIIIb or ZMB3/MXIIIb, by the calcium phosphate method. For stable expression, 48 h after transfection cells were grown in the culture medium containing 5 mg/ml G418 (GIBCO BRL) as a selective agent. After -10 d, G418-resistant colonies were isolated and propagated individually in the selection medium containing G418. All cell cultures were maintained in a humidified 5% CO2 incubator at 370C.
ELISA and Immunoblotting of culture media and cell lysates. Cells expressing the wild type or mutant b subunit were cultured in 100-mm dishes (Falcon, Oxnard, CA). After washing with phosphate buffered saline (PBS), the cells were cultured further in 6 ml of culture medium without FCS (serum-free medium). The culture media were harvested after 24 h, and the cells were washed with PBS and lysed in 3 ml of a detergent solution containing 10 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 5 mM EDTA, 1% sodium deoxycholate, 1% Triton X-100, and 0.1% SDS.
Concentrations of the wild-type and mutant b subunits in culture media and cell extracts were measured by ELISA, using a rabbit polyclonal antibody against human b subunit (Calbiochem Corp., La Jolla, CA) as the primary antibody, and a peroxidase-conjugated goat antirabbit IgG antibody (Bio Rad Laboratories, Richmond, CA) as the secondary antibody. ELISAs were developed with 3, 3', 5,5 '-tetramethylbenzidine as the colorimetric substrate (Bio Rad), followed by 0.1% H202-For Western blotting, three volumes of culture media or cell lysates were mixed with one volume of 4x sample buffer (125 mM Tris-HCI, pH 6.8, 4% SDS, 50% glycerol, and 1 mg/ml bromophenol blue) and boiled for 5 min; then 50 Al of aliquots were electrophoresed on 8% polyacrylamide gels under reducing and nonreducing conditions. Samples were also analyzed by nondenatured polyacrylamide gel electrophoresis without SDS as described by Lorand et al. (17) . The separated proteins were transferred onto 0.2 ,tm Polyvinylidene fluoride (PVDF) membranes (Atto Corp., Japan) using a semi-dry electroblotter. The membrane was then blocked at room temperature for 1 h using a Western buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 0.05% NP-40, 0.15 M NaCl, and 0.25% gelatin, and incubated at room temperature for 1 (Fig. 2, left  panel) . The apparent molecular weight of the mutant b subunit, however, was slightly higher than that of the wild type (-85 kD). It is very likely that the mutant molecule is extended because one of two disulfide bonds in the seventh Sushi domain is absent. This explanation is consistent with the fact that there was no difference in the apparent molecular weights of the two molecules when the samples were reduced with f-mercaptoethanol (Fig. 2, right panel) .
A band, which may represent a disulfide-bonded covalent dimer of the mutant b subunit, was observed under nonreducing conditions, but disappeared upon reduction. A Pulse-chase experiments were also performed successfully in the transient expression system. This was possible because of the advantage radiolabeling of proteins has over Western blotting by virtue of high sensitivity. As seen in the stable expression system, the wild type b subunit was secreted quantitatively and the mutant was not released from cells in the transient expression system (Fig. 4) . These results strongly suggest that the intracellular transport of the mutant b subunit is impaired.
The pulse-chase experiments used with COS-7 cells provided the same results as described above in BHK cells (data not shown).
Endoglycosidase treatment of intracellular b subunits. Because the wild-type b subunit is secreted from synthesizing cells, while the mutant is not, it could be that the mutant is trapped at some stage(s) in the secretary pathway and does not undergo normal posttranslational processing. To examine Asnlinked oligosaccharide processing of the mutant b subunit, both cell lysates and culture media were incubated with or without endo H, an enzyme with specificity for immature, high-mannose type oligosaccharide side chains.
The wild-type b subunit in the cell lysates was sensitive to endo H digestion at 0 h, and became resistant after 1 h (Fig.  5) . Contrary to the wild type, the intracellular mutant remained susceptible to endo H during the observed period, indicating that the mutant was retained in a compartment(s) before the medial-Golgi. These results strongly suggest that intracellular transport of the mutant was blocked between the ER and the Golgi apparatus where processing of oligosaccharides occurs. Immunocytochemistry. To investigate the subcellular localization of the b subunit, immunocytochemical studies were performed. Fig. 6 shows the immunofluorescence microscopy of three different samples: BHK cells producing the mutant, the wild-type b subunit, and mock cells as a negative control. Bright diffuse fluorescence of a fine punctuate/reticular pattern characteristic of ER labeling was observed when the cells producing the mutant reacted with the anti-b subunit antiserum (Fig. 6  A) . Control cells showed no significant fluorescence (Fig. 6  C) . This staining pattern is consistent with our hypothesis that the mutant protein remains in the ER (ER retention). In contrast to the cells expressing the mutant, a prominent signal, appearing as a stacked and compact structure near the cell nucleus (Fig.  6 B) , was observed in addition to a weak diffuse fluorescence pattern inside the cells producing the wild-type b subunit. Although the localization of the b subunit in the cells cannot be absolutely determined by the light microscopic study, these results strongly suggest that the normal protein is present in the Golgi apparatus as well as in the ER. Thus, it is very likely that the wild-type b subunit was transported from the ER to the Golgi apparatus where processing of oligosaccharides occurs, while the mutant was retained in the ER. The impaired intracellular transport of the mutant b subunit can account for its deficiency in this case because the newly synthesized mutant b subunit never reaches circulation.
Discussion
The five examples of factor XHI deficiency in which the mutation is known (10-13) all result from genetic defects of the a subunit. However, an inherited quantitative abnormality of the b subunit also results in factor XIII deficiency, which is characterized by mild bleeding symptoms (4). In the previous report (14) , we determined two genetic mutations in the first patient who has been diagnosed as having complete b subunit deficiency. One of the two mutations, Cys430(TGC)-Phe(TTC) is the only missense mutation to be described to date that causes the b subunit deficiency, the mechanism(s) for which is unclear.
In order to determine whether the Cys430-Phe mutation does indeed give rise to the observed phenotype, constructs bearing Wild Type wild-type and mutant b subunit were transfected into BHK cells. Such a mammalian expression system allows elucidation of the structural as well as functional consequences of the mutation in its biosynthesis.
The present studies demonstrated that the Cys430-Phe mutation does not prevent the de novo synthesis of the b subunit.
Since fairly large amounts of the mutant b subunit were detected inside the cells of stable expression, severe defects in its transcription and/or translation are unlikely to have dramatic effects. Extracellular degradation of the mutant molecule was also excluded since no evidence was found when degradation in culture media was monitored over time. Instead, it has been clearly shown that the Cys430-Phe substitution impairs the secretion of newly synthesized mutant b subunit (Figs. 3 and 4) . 5) . Thus, it was concluded that the mutant b subunit never reached the medial Golgi, and that the intracellular transport of the mutant b subunit is impaired in BHK cells. Impaired intracellular transport of mutant proteins is considered to be a general mechanism for various protein deficiencies (25) (26) (27) (28) (29) (30) . In most cases, the cause of impaired transport of mutants was attributed to ER retention because of the sensitivity to endo H treatment. Few trapped mutant proteins were actually shown to be localized inside the ER (26, 30) . In the present study, the mutant b subunit was shown by immunocytochemistry to remain exclusively inside the synthesizing cells (Fig. 6 ), very likely in the ER. However, the precise mechanisms for the ER retention per se are not known. The pronounced homology among Sushi domain-containing proteins permits an alignment of highly conserved amino acid residues (7, 9) . In particular, four Cys residues in each Sushi domain are found in identical positions in every member of this protein superfamily. The first and third, and the second and fourth Cys residues are linked together, forming two disulfide bonds (31, 32) . It is likely that the secondary and three-dimensional structures of Sushi domains are also similar (33) (34) (35) . The loss of a Cys residue by the Cys430-Phe substitution disrupts the Cys430-Cys4O5 disulfide bond in the seventh Sushi domain of the b subunit and leaves Cys4O5 unpaired. The resulting seventh Sushi domain may alter its gross conformation, likely becoming more extended than the normal molecule which is compacted by two disulfide bonds. The difference in electrophoretic mobility shown in Fig. 2 Proteins that have been retained in the ER because of improper folding and/or aberrant posttranslational processing are eventually degraded (37, 38) . Thus, the misfolded mutant b subunit may become a target of degradation systems inside hepatocytes. In the case of the mutant b subunit expressed in BHK cells, it is evident that the protein is degraded in these cells since intracellular accumulation of the newly synthesized mutant b subunit molecule is not prominent.
In the case of a1-antitrypsin deficiency, intrahepatocyte defects in a1-antitrypsin biosynthesis associated with its mutations are manifest in like manners in all heterologous cells including fibroblasts, kidney cells, and monocytes (19) (20) (21) (22) (23) . It is reasonable to assume that the abnormal intracellular transport of the mutant in BHK and COS-7 cells also occurs in hepatocytes and that the abnormal b subunit never reaches circulation since the proband manifests complete deficiency. Direct evidence is not available, however, because liver biopsy of the proband has not been performed. Hepatoma cells were not employed for these experiments because they synthesize endogenous b subunit (unpublished data), which hampers analyses.
Before the first case of complete b subunit deficiency was found in Japan (4), several patients demonstrating similar laboratory findings had been reported in Italy (39-41). These patients were classified as type I factor XIII deficiency, which is characterized by the absence of both a and b subunits (39) . They may have separate defects in both genes by chance, resulting in real combined deficiency of both subunits. Alternatively, reduced plasma a subunit levels in these cases may be secondary to the b subunit deficiency, in the same manner as the Japanese case (4) . Amounts of the a subunit in platelets were not described in the reports for these Italian cases (39) (40) (41) . If there is no a subunit in platelets (or placenta), the a subunit deficiency is independent from the b subunit deficiency. If normal amounts of the a subunit are present in platelets, the gene for the a subunit must be normal and that for the b subunit must have some defect(s). To examine both genes 
